Immunitybio announces biological license application resubmission for n-803 in bcg-unresponsive non-muscle-invasive bladder cancer carcinoma-in-situ

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), a clinical-stage immunotherapy company, today announced it has completed the resubmission of its biologics license application (bla) to the u.s. food and drug administration (fda) for n-803 (anktiva®), a first-in-class il-15 superagonist, plus bacillus calmette-guÉrin (bcg) for the treatment of bcg-unresponsive non-muscle-invasive bladder cancer carcinoma in situ (cis) with or without ta or t1 disease. the bla is supported.
IBRX Ratings Summary
IBRX Quant Ranking